119 results
8-K
EX-99.1
NTBL
Notable Labs Ltd
12 Apr 24
Notable Labs Reports 2023 Financial Results and Provides a Business Update
8:44am
for the year ended December 31, 2023 was $0.2 million.
Research and development expenses for the year ended December 31, 2023 were $4.7 million, compared
8-K/A
EX-99.3
NTBL
Notable Labs Ltd
29 Nov 23
Financial Statements and Exhibits
5:15pm
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income, net
Net income (loss) per share, basic … , Ltd. is unable to raise capital when needed or on attractive terms, it may be forced to delay, reduce or eliminate its research and development
8-K/A
EX-99.4
NTBL
Notable Labs Ltd
29 Nov 23
Financial Statements and Exhibits
5:00pm
Pro Forma Combined
Note A
Note B
Note C
Revenue
Cost of revenues
Gross profit
Operating expenses:
Research and development expenses, net
General …
Transaction Accounting Adjustments
Notes
Pro Forma Combined
Note A
Note B
Note C
Revenue
Cost of revenues
Gross profit
Operating expenses:
Research
8-K/A
EX-99.3
kivt93l6vtbkfg
29 Nov 23
Financial Statements and Exhibits
5:00pm
8-K/A
EX-99.2
3se toq2t
29 Nov 23
Financial Statements and Exhibits
5:00pm
425
EX-10.1
exarok75 qxk
2 Oct 23
Business combination disclosure
5:31pm
8-K
EX-10.1
srpd0dvz
2 Oct 23
Other Events
5:30pm
424B3
xd7 1uew2skr5i6x8
2 Oct 23
Prospectus supplement
5:29pm
424B3
ykr8b9vzs2l
5 Sep 23
Prospectus supplement
6:02pm
425
EX-99.1
3gw15p 241h
14 Aug 23
Business combination disclosure
8:06am
8-K
EX-99.1
knxlp
14 Aug 23
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
8:05am
S-4/A
6rfmx vf6elhu63eut6
30 Jun 23
Registration of securities issued in business combination transactions (amended)
4:38pm
10-Q
ugyxeyj 0n1
15 May 23
Quarterly report
4:30pm